Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases.
The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. It is based on the discovery of modified synthetic peptides - Imotopes, which specifically block improper immune responses. Thus representing a next generation, potentially curative approach to severe chronic autoimmune diseases for which there is no satisfactory therapeutic alternative.
The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopefor the treatment of several autoimmune diseases. Founded as a spin-off of the Catholic University of Leuven (KULeuven) in 2011, Imcyse subsequently relocated to Liège, Belgium. The company has strong support from local investors from the Wallonia region as well as public and government funds and completed a Series B financing in mid-2019 with a strong international VC syndicate.